 AN OPEN LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF DEFERASIROX ADMINISTERED TO CHINESE PATIENTS WITH Β-THALASSEMIA MAJOR AGED FROM 2 TO LESS THAN 6 YEARS OLD: 